UY39863A - Compuestos y composiciones para el tratamiento de enfermedades relacionadas con el coronavirus - Google Patents

Compuestos y composiciones para el tratamiento de enfermedades relacionadas con el coronavirus

Info

Publication number
UY39863A
UY39863A UY0001039863A UY39863A UY39863A UY 39863 A UY39863 A UY 39863A UY 0001039863 A UY0001039863 A UY 0001039863A UY 39863 A UY39863 A UY 39863A UY 39863 A UY39863 A UY 39863A
Authority
UY
Uruguay
Prior art keywords
compounds
compositions
treatment
coronavirus
related diseases
Prior art date
Application number
UY0001039863A
Other languages
English (en)
Spanish (es)
Inventor
Lei Shi
Bo Liu
Matthew James Hesse
Denghui Bao
Fengfeng Guo
Viktor Hornak
Sajan Joseph
Jr Thomas Martin Kirrane
Haiyao Lin
yanan Miao
Heinz Ernst Moser
Julien Papillon
Yang Qu
Jun Yuan
Teng Zhang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY39863A publication Critical patent/UY39863A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UY0001039863A 2021-07-22 2022-07-19 Compuestos y composiciones para el tratamiento de enfermedades relacionadas con el coronavirus UY39863A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163224793P 2021-07-22 2021-07-22
US202163289009P 2021-12-13 2021-12-13

Publications (1)

Publication Number Publication Date
UY39863A true UY39863A (es) 2023-02-28

Family

ID=82742919

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039863A UY39863A (es) 2021-07-22 2022-07-19 Compuestos y composiciones para el tratamiento de enfermedades relacionadas con el coronavirus

Country Status (11)

Country Link
US (1) US20250092016A1 (https=)
EP (1) EP4373814A1 (https=)
JP (1) JP2024527424A (https=)
KR (1) KR20240038996A (https=)
AU (1) AU2022315058A1 (https=)
CA (1) CA3226758A1 (https=)
MX (1) MX2024000986A (https=)
PY (1) PY2261702A (https=)
TW (1) TW202321210A (https=)
UY (1) UY39863A (https=)
WO (1) WO2023002409A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL300412A (en) 2020-08-24 2023-04-01 Gilead Sciences Inc Phospholipid compounds and their uses
TW202344257A (zh) 2020-10-16 2023-11-16 美商基利科學股份有限公司 磷脂化合物及其用途
AU2022306289A1 (en) 2021-07-09 2024-01-18 Aligos Therapeutics, Inc. Anti-viral compounds
JP7624093B2 (ja) 2022-04-08 2025-01-29 塩野義製薬株式会社 ウイルス増殖阻害活性を有するウラシル誘導体およびそれらを含有する医薬組成物
WO2024031089A1 (en) 2022-08-05 2024-02-08 Gilead Sciences, Inc. Sars-cov2 main protease inhibitors
WO2025125695A2 (en) * 2024-12-17 2025-06-19 Medchemica Consultancy Ltd Chemical compoundsid50000167790940 p. doc 2025-05-07 filing no.:19

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1200825B (de) * 1962-01-13 1965-09-16 Hoechst Ag Verfahren zur Herstellung von 3, 5-Dioxo-triazolidinen
WO2010149755A1 (en) * 2009-06-26 2010-12-29 Novartis Ag 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17

Also Published As

Publication number Publication date
MX2024000986A (es) 2024-02-12
PY2261702A (es) 2023-06-14
TW202321210A (zh) 2023-06-01
KR20240038996A (ko) 2024-03-26
US20250092016A1 (en) 2025-03-20
EP4373814A1 (en) 2024-05-29
AU2022315058A1 (en) 2024-02-08
CA3226758A1 (en) 2023-01-26
WO2023002409A1 (en) 2023-01-26
JP2024527424A (ja) 2024-07-24

Similar Documents

Publication Publication Date Title
UY39863A (es) Compuestos y composiciones para el tratamiento de enfermedades relacionadas con el coronavirus
CL2021003477A1 (es) Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8
BR112022012106A2 (pt) Inibidores de sos1
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
MX2023001689A (es) Inhibidores de bcl-2.
MX2024012801A (es) Inhibidores de parp1 de azetidina y pirrolidina y usos de estos
CL2022002695A1 (es) Inhibidores de rip1k
UY38403A (es) Moduladores de la alfa-1 antitripsina
CO2026004964A2 (es) Moduladores de kras
MX2020011868A (es) Inhibidores de los receptores erbb.
MX2020007947A (es) Inhibidores de erbb/btk.
MX2021002805A (es) Terapias de combinacion.
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
CL2020001349A1 (es) Compuestos, composición y uso de los mismos como moduladores de la expresión de pcsk9. (divisional solicitud 201902574)
MX2024014861A (es) Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo
DOP2002000525A (es) Inhibidores del factor xa y de otras proteasas de serina implicadas en la cascada de la coagulacion.
MX2022013081A (es) Compuestos para el tratamiento de sars.
ECSP20082339A (es) Moduladores de la expresión de apol1
UY27800A1 (es) Utilizacion de inhibidores de la transduccion de senales inducida por egfr para el tratamiento de la hiperplasia de la prostata benigna (hps) /hipertrofia de la prostata.
CL2022000214A1 (es) Inhibidores de enzimas
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
CO2022000266A2 (es) Inhibidores de enzimas
PA8555501A1 (es) Compuestos de benzimidazol sustituido y su uso para el tratamiento del cancer
MX2023005530A (es) Metodos y composiciones que comprenden un inhibidor de krasg12c y un antagonista de union a pd-l1 para tratar cancer de pulmon.
MX2024014771A (es) Terapia combinada